Analysis of Ribociclib Finds it is Not Cost-Effective Despite Significant Survival Benefit
Ribociclib is approved for use in combination with an
aromatase inhibitor for the first-line treatment of pre- and perimenopausal
women with hormone receptor-positive, human...
Cost Comparison of Two Influenza Vaccines for Older Adults
Adjuvanted trivalent influenza vaccine (aTIV) and trivalent
high dose influenza vaccine (TIV-HD) have shown different clinical benefits, so
researchers assessed the annualized mean all-cause...
Health Policy Changes on the Horizon in an Election Year
A variety of health policy proposals have been rolled out in
the face of an election year where health care is a top...
How to Manage High-Cost Gene and Cell Therapies
Gene and cell therapies are high-cost drugs that are
increasingly becoming burdensome to the health care system. During a
presentation at AMCP eLearning Days,...